A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT06718101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple substudies. Substudy 1 will have a randomized, open-label period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Substudy 1, participants will receive subcutaneous (SC) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of SC injections of lutikizumab every other week for a total of 52 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.
Study identification
- NCT ID
- NCT06718101
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2024 (Actual)
- Primary completion
- May 2027 (Estimated)
- Completion
- May 2027 (Estimated)
- Last update posted
- Aug 14, 2026
2024 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550 | Fountain Hills | Arizona | 85268 | — |
| Dermatology Research Associates - Los Angeles /ID# 272945 | Los Angeles | California | 90045 | — |
| Integrative Skin Science and Research /ID# 274243 | Sacramento | California | 95815 | — |
| Clinical Trials Research Institute /ID# 274234 | Thousand Oaks | California | 91320 | — |
| Western States Clinical Res /ID# 271748 | Wheat Ridge | Colorado | 80033-2896 | — |
| Skin Care Research Boca Raton /ID# 272544 | Boca Raton | Florida | 33486-2269 | — |
| Research Associates of South Florida /ID# 272549 | Miami | Florida | 33134 | — |
| Advanced Clinical Research Institute - Tampa /ID# 272558 | Tampa | Florida | 33607 | — |
| Encore Medical Research - Weston /ID# 272539 | Weston | Florida | 33331 | — |
| Arlington Dermatology /ID# 271735 | Rolling Meadows | Illinois | 60008 | — |
| Somnos Clinical Research /ID# 272943 | Lincoln | Nebraska | 68510 | — |
| Equity Medical /ID# 272555 | New York | New York | 10023-7340 | — |
| Oregon Dermatology and Research Center /ID# 271733 | Portland | Oregon | 97210 | — |
| Clinical Partners /ID# 271791 | Johnston | Rhode Island | 02919 | — |
| Health Concepts /ID# 271744 | Rapid City | South Dakota | 57702 | — |
| Orion Clinical Research /ID# 274236 | Austin | Texas | 78759 | — |
| Complete Dermatology - Sugar Land /ID# 274240 | Sugar Land | Texas | 77479 | — |
| Dermatology Associates of Tyler /ID# 273684 | Tyler | Texas | 75703 | — |
| Center for Clinical Studies - Clear Lake /ID# 271749 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06718101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06718101 live on ClinicalTrials.gov.